Trials / Completed
CompletedNCT05441501
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
A Phase 1 Study of JNJ-80038114, a T-Cell Redirecting Agent Targeting Prostate Specific Membrane Antigen (PSMA), for Advanced Stage Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-80038114 in Part 1 (dose escalation) and to determine the safety at the RP2D(s) in Part 2 (dose expansion).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-80038114 | JNJ-80038114 will be administered. |
Timeline
- Start date
- 2022-11-15
- Primary completion
- 2024-03-26
- Completion
- 2024-03-31
- First posted
- 2022-07-01
- Last updated
- 2025-03-04
Locations
6 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05441501. Inclusion in this directory is not an endorsement.